RxDoctor Payments Data

William Tanner, MD

Gastroenterology · Lawrenceville, GANPI 1114911294

Payments from drug & device makers

$8,355in general payments, 2019–2025

Across 506 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$896
  • Gilead$827
  • Sanofi$434
  • Takeda Pharmaceuticals U.S.A., Inc.$419
  • Johnson & Johnson$401
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$8,355100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,355 in reported general payments places this provider in the 70th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$196,322
Medicare patients
765
Services billed
1,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$173,827
Humira(Cf)Adalimumab12$92,694
XifaxanRifaximin23$74,880
LinzessLinaclotide59$63,694
VemlidyTenofovir Alafenamide16$31,056
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl600$13,947
MovantikNaloxegol Oxalate18$8,789
Mesalamine17$7,698
DexilantDexlansoprazole18$7,663
Mesalamine ErMesalamine27$6,528
Pantoprazole Sodium499$6,454
Ursodiol53$6,388
Omeprazole666$6,212
Sucralfate152$5,929
Budesonide EcBudesonide27$4,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Linzess$2,087$156,38871 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$896$74,88023 claims
GileadVemlidy$827$31,05616 claims
Redhill Biopharma Inc.Movantik$38$8,78918 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$419$7,66318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →